What is the most reliable diagnostic test to confirm breast cancer?

Best Diagnostic Test for Breast Cancer

Core needle biopsy (preferably obtained by ultrasound or stereotactic guidance) is the gold standard diagnostic test to confirm breast cancer, and must be obtained before initiating any treatment. 1, 2

Diagnostic Algorithm

Initial Detection and Imaging Work-up

When breast cancer is suspected, the diagnostic pathway follows this sequence:

1. Clinical examination - Bimanual palpation of breasts and regional lymph nodes 2

2. Bilateral mammography and ultrasound - Both breasts and regional lymph nodes must be evaluated 1, 2

   • Digital breast tomosynthesis or contrast-enhanced mammography can be considered as alternatives where available 1

3. Breast MRI - Reserved for specific situations 1, 2:

   • Familial breast cancer with BRCA mutations
   • Lobular cancers
   • Dense breasts
   • Suspected multifocality/multicentricity
   • Before neoadjuvant therapy
   • When conventional imaging is inconclusive

Definitive Tissue Diagnosis

Core needle biopsy is mandatory and superior to fine-needle aspiration for the following reasons 2:

• Minimum 2-3 cores should be obtained to ensure adequate tissue
• Allows assessment of invasive versus in situ disease
• Enables biomarker testing (ER, PgR, HER2, Ki67)
• Must be performed before any treatment initiation 2

A surgical clip or carbon marker must be placed at biopsy to ensure correct site resection and enable pathological assessment 2

Special Circumstances

For multifocal/multicentric tumors: All lesions must be biopsied 2

For suspicious lymph nodes: US-guided fine-needle aspiration or core biopsy should be performed, preferably with clip or carbon marking 2

Excisional biopsy should NOT be performed except in rare cases of repeated negative core biopsies 2

Common Pitfalls to Avoid

• Never start treatment without histological confirmation - Core biopsy is non-negotiable 2
• Don't rely on fine-needle aspiration alone - While it has high accuracy (98% sensitivity in some studies 3), it cannot distinguish invasive from in situ disease
• Don't skip marker placement - This is essential for surgical planning 2
• Don't perform excisional biopsy as first-line - This compromises subsequent surgical planning 2

Quality Standards

Final pathological diagnosis must follow:

• WHO classification of tumours
• Eighth edition of UICC TNM staging system 1, 2

The "triple test" (clinical examination + imaging + cytology) mentioned in older literature 4, 5 has been superseded by the requirement for core needle biopsy with full biomarker assessment in current guidelines 1, 2.